Form 8-K SAB Biotherapeutics, For: Dec 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
SAB Biotherapeutics establishes $75 million at-the-market offering program
December 29, 2025 4:02 PM ESTSAB Biotherapeutics Inc. (NASDAQ: SABS) entered into a sales agreement with UBS Securities LLC on December 29 to establish an at-the-market offering program allowing the company to sell up to $75 million of common stock.
Under the agreement, UBS will act as sales agent for... More
